Given the known dysregulation of CRLs and the observed upregulation of CUL4A and CUL4B in a variety of cancers, we leveraged this inverse precision medicine approach to identify patient populations that might benefit from CRL4 inhibition and to dissect the functional roles of the CRL4 complex in sensitive tumours. This evidence concerns the gene CUL4B and neoplasm.